Welcome to our dedicated page for Chemours Co SEC filings (Ticker: CC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Chemours Company filings document formal disclosures for a NYSE-listed global chemistry company with businesses in Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials. Recent Form 8-K reports furnish operating results and financial condition updates, including segment commentary on Opteon refrigerants, TiO2 pigment, and other specialty-chemistry markets.
Regulatory filings also cover capital-structure actions, including senior unsecured notes, indentures, guarantees, and redemption of outstanding debt. Definitive proxy materials document board structure, director elections, advisory compensation votes, auditor ratification, equity-incentive plan approval, and other shareholder voting matters.
CRANSTON MARY B reported acquisition or exercise transactions in this Form 4 filing.
Chemours Co director Mary B. Cranston received an equity grant of 7,182 shares of common stock on May 6. The award was granted at no cash cost to her, reflecting stock-based compensation rather than an open-market purchase.
After this grant and an adjustment to correct an administrative error in prior filings, her direct and deferred holdings now total 106,830.0129 shares, including deferred stock units and related dividend equivalent units.
Chemours director Leslie M. Turner received a grant of 7,182 stock units of Chemours common stock on May 6, 2026. The units were awarded at no cash cost and increase Turner’s direct holdings to 24,603.3891 stock units.
According to the footnotes, these stock units, including deferred stock units and dividend equivalent units, will convert one-for-one into Chemours common stock when Turner separates from service on the Board. This reflects routine equity-based board compensation rather than an open-market purchase.
Chemours Co director Pamela Fletcher received a grant of 7,182 shares of Common Stock on May 6, 2026, as a stock award. The shares were awarded at a price of $0.00 per share as compensation, not an open-market purchase.
The award represents stock units that will convert one-for-one into Chemours common stock upon her separation from service on the Board and includes deferred stock units and dividend equivalent units. After this grant, Fletcher directly holds a total of 32,382.9997 shares of Chemours common stock.
Chemours director Alister Cowan reported a grant of 7,182 stock units of Chemours common stock. The units were acquired at a stated price of $0.00 per share as a compensation award. Following this grant, Cowan directly holds 43,881.0397 shares or stock units in total.
The granted stock units, including deferred stock units and dividend equivalent units, will convert one-for-one into Chemours common stock when Cowan separates from service on the Board.
Chemours director Courtney Mather received a grant of 7,182 stock units of Chemours common stock on May 6, 2026. These stock units will convert one-for-one into Chemours common shares upon separation from service on the Board and include deferred and dividend equivalent units. Following this award, Mather holds a total of 21,642.7173 stock units directly.
Chemours Co director Erin N. Kane received a grant of 7,182 Chemours common stock units as board compensation. The award was recorded at a price of $0.00 per unit and increases Kane’s directly held stock units to 74,062.9086.
The footnotes explain these are stock units that will convert one-for-one into Chemours common shares when Kane separates from service on the Board, and that the total includes both deferred stock units and related dividend equivalent units. This is a non-cash, routine equity award rather than an open-market purchase.
Chemours Co director Livingston Satterthwaite received an equity award of 7,182 stock units of Chemours common stock as board compensation. The units were granted at no cash cost to the director and will convert one-for-one into Chemours common shares upon separation from board service.
The award includes deferred stock units and related dividend equivalent units, increasing Satterthwaite’s directly held balance to 30,807.855 shares and stock units combined after this transaction.
Chemours Co director Sean D. Keohane received a grant of 7,182 stock units of Chemours common stock at a price of $0.00 per unit. These stock units will convert one-for-one into Chemours common stock when he separates from service on the Board.
The grant includes deferred stock units and related dividend equivalent units. Following this award, Keohane holds a total of 72,555.1777 shares and stock units of Chemours common stock directly.
Chemours director Joseph Daniel Kava received a grant of 7,182 stock units of Chemours common stock. The units were awarded at a price of $0.00 per share as board compensation. Following this award, Kava directly holds a total of 24,603.3891 stock units. According to the disclosure, these stock units will convert one-for-one into Chemours common stock when Kava separates from service on the Board, and the total includes both deferred stock units and related dividend equivalent units.
Brokaw George R reported acquisition or exercise transactions in this Form 4 filing.
Director George R. Brokaw of Chemours Co received an award of 7,182 shares of Common Stock on May 6, 2026. The shares were granted at $0.00 per share as compensation rather than a market purchase. Following this grant, his direct holdings, including deferred stock units and dividend equivalent units, total 21,642.7173 shares of Chemours common stock.